Skip to main content

Fluticasone / umeclidinium / vilanterol News

FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of Asthma

London UK 9 September 2020 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy...

Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD

24 April 2018 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy...

FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD

London UK – 18 September 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single i...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Chronic Obstructive Pulmonary Disease, Asthma

Related drug support groups

Trelegy Ellipta

Fluticasone / umeclidinium / vilanterol patient information at Drugs.com